Prevalence, etiology, and treatment of depression in Parkinson's disease

Biological Psychiatry

Volumn 54, Issue 3, 2003, Pages 363-375

  McDonald, William M ^a,c   Richard, Irene H ^b   DeLong, Mahlon R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Wesley Woods Geriatric Hospital   (United States)

Author keywords

Anxiety; Dementia; Depression; Parkinson disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PHENELZINE; PRAMIPEXOLE; RESERPINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE DISTRIBUTION; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BRAIN CORTEX; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CORRELATION ANALYSIS; DELIRIUM; DEMENTIA; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; INCIDENCE; INSOMNIA; MELANCHOLIA; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NERVE DEGENERATION; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT;

ANTIPARKINSON AGENTS; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; PARKINSON DISEASE; PREVALENCE;

EID: 0141832608     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00530-4     Document Type: Review

References (133)

1. Aarsland D., Laake K., Larsen J.P., Janvin C. Donepezil for cognitive impairment in Parkinson's disease A randomised controlled study . [erratum appears in J Neurol Neurosurg Psychiatry 2002 Sep;73(3):354] J Neurol Neurosurg Psychiatry. 72:2002;708-712.
2. Aarsland D., Larsen J.P., Waage O., Langeveld J.H. Maintenance electroconvulsive therapy for Parkinson's disease. Convuls Ther. 13:1997;274-277.
3. Allain H., Schuck S., Mauduit N. Depression in Parkinson's disease. BMJ. 320:2000;1287-1288.
4. Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;APA Press, Washington, DC.
5. Andersen J., Aabro E., Gulmann N., Hjelmsted A., Pedersen H.E. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand. 62:1980;210-219.
6. Barrett-Connor E., Von Muhlen D.G., Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men The Rancho Bernardo Study . J Clin Endocrinol Metab. 84:1999;573-577.
7. Beck A., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 4:1961;561-571.
8. Becker T., Becker G., Seufert J., Hofmann E., Lange K.W., Naumann M., et al. Parkinson's disease and depression Evidence for an alteration of the basal limbic system detected by transcranial sonography . J Neurol Neurosurg Psychiatry. 63:1997;590-596.
9. Bejjani B.P., Damier P., Arnulf I., Thivard L., Bonnet A.M., Dormont D., et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 340:1999;1476-1480. [comment].
10. Ben-Shlomo Y., Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonism Possible clues to aetiology? J Neurol Neurosurg Psychiatry. 58:1995;293-299.
11. Berger J.R., Kelley R.E. Thyroid function in Parkinson disease. Neurology. 31:1981;93-95.
12. Bergman J., Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 25:2002;107-110.
13. Berney A., Vingerhoets F., Perrin A., Guex P., Villemure J.G., Burkhard P.R., et al. Effect on mood of subthalamic DBS for Parkinson's disease A consecutive series of 24 patients . Neurology. 59:2002;1427-1429. [comment].
14. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol. 62:2000;63-88.
15. Bottiglieri T., Laundy M., Crellin R., Toone B.K., Carney M.W., Reynolds E.H. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 69:2000;228-232. [comment].
16. Bouchard R., Pourcher E., Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 146:1989;1352-1353.
17. Brattstrom L. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 56:2001;281-282. [comment].
18. Brown A.S., Gershon S. Dopamine and depression. J Neural Transm Gen Sect. 91:1993;75-109.
19. Brown R.G., MacCarthy B., Gotham A.M., Der G.J., Marsden C.D. Depression and disability in Parkinson's disease A follow-up of 132 cases . Psychol Med. 18:1988;49-55.
20. Caley C.F., Friedman J.H. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry. 53:1992;278-282.
21. Cantello R. Applications of transcranial magnetic stimulation in movement disorders. J Clin Neurophysiol. 19:2002;272-293.
22. Cantello R., Gilli M., Riccio A., Bergamasco B. Mood changes associated with "end-of-dose deterioration" in Parkinson's disease A controlled study . J Neurol Neurosurg Psychiatry. 49:1986;1182-1190.
23. Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl. 51:1972;11-42.
24. Ceravolo R., Nuti A., Piccinni A., Dell'Angello G., Bellini G., Gambaccini G., et al. Paroxetine in Parkinson's disease Effects on motor and depressive symptoms . Neurology. 55:2000;1216-1218.
25. Cole S.A., Woodard J.L., Juncos J.L., Kogos J.L., Youngstrom E.A., Watts R.L. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 8:1996;20-25.
26. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 11:2000;58-65.
27. Cummings J.L. Depression and Parkinson's disease A review . Am J Psychiatry. 149:1992;443-454. [comment].
28. Dell'Agnello G., Ceravolo R., Nuti A., Bellini G., Piccinni A., D'Avino C., et al. SSRIs do not worsen Parkinson's disease Evidence from an open-label, prospective study . Clin Neuropharmacol. 24:2001;221-227.
29. Di Rocco A., Rogers J.D., Brown R., Werner P., Bottiglieri T. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord. 15:2000;1225-1229.
30. Dooneief G., Mirabello E., Bell K., Marder K., Stern Y., Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol. 49:1992;305-307.
31. Dragasevic N., Potrebi A., Damjanovi A., Stefanova E., Kosti V.S. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease An open study . Mov Disord. 17:2002;528-532.
32. Edwards E., Kitt C., Oliver E., Finkelstein J., Wagster M., McDonald W.M. Depression and Parkinson's disease A new look at an old problem . Depress Anxiety. 16:2002;39-48.
33. Ehmann T.S., Beninger R.J., Gawel M.J., Riopelle R.J. Depressive symptoms in Parkinson's disease A comparison with disabled control subjects . J Geriatr Psychiatry Neurol. 3:1990;3-9.
34. Fall P.A., Ekman R., Granerus A.K., Thorell L.H., Walinder J. ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect. 10:1995;129-140.
35. Fall P.A., Granerus A.K. Maintenance ECT in Parkinson's disease. J Neural Transm. 106:1999;737-741.
36. Friedenberg D.L., Cummings J.L. Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics. 30:1989;94-99.
37. George M.S., Lisanby S.H., Sackeim H.A. Transcranial magnetic stimulation Applications in neuropsychiatry . Arch Gen Psychiatry. 56:1999;300-311. [comment].
38. Giladi N., Treves T.A., Paleacu D., Shabtai H., Orlov Y., Kandinov B., et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm. 107:2000;59-71.
39. Factors impacting on quality of life in Parkinson's disease Results from an international survey . Mov Disord. 17:2002;60-67.
40. Goetz C.G., Tanner C.M., Klawans H.L. Bupropion in Parkinson's disease. Neurology. 34:1984;1092-1094.
41. Green J., McDonald W.M., Vitek J.L., Haber M., Barnhart H., Bakay R.H., et al. Neuropsychological and psychiatric sequelae of pallidotomy for PD Clinical trial findings . Neurology. 58:2002;858-865.
42. Groenewegen H.J., Berendse H.W. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. J Comp Neurol. 294:1990;607-622.
43. Guze B.H., Barrio J.C. The etiology of depression in Parkinson's disease patients. Psychosomatics. 32:1991;390-395.
44. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
45. Hardie R.J., Lees A.J., Stern G.M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 107:1984;487-506.
46. Hauser R.A., Zesiewicz T.A. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 12:1997;756-759. [comment].
47. Hesselink J.M. Serotonin and Parkinson's disease. Am J Psychiatry. 150:1993;843-844. [comment].
48. Horwath E., Johnson J., Klerman G.L., Weissman M.M. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry. 49:1992;817-823.
49. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 54:2000;1596-1602.
50. Jellinger K.A. Post mortem studies in Parkinson's disease-Is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl. 56:1999;1-29.
51. Jimenez-Jimenez F.J., Tejeiro J., Martinez-Junquera G., Cabrera-Valdivia F., Alarcon J., Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology. 44:1994;2406.
52. Judd L.L., Paulus M.P., Wells K.B., Rapaport M.H. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry. 153:1996;1411-1417.
53. Judd L.L., Rapaport M.H., Paulus M.P., Brown J.L. Subsyndromal symptomatic depression A new mood disorder? J Clin Psychiatry. 55:(suppl):1994;18-28. [comment].
54. Koenig H.G., George L.K., Peterson B.L., Pieper C.F. Depression in medically ill hospitalized older adults Prevalence, characteristics, and course of symptoms according to six diagnostic schemes . Am J Psychiatry. 154:1997;1376-1383.
55. Kostic V.S., Filipovic S.R., Lecic D., Momcilovic D., Sokic D., Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;1265-1267.
56. Krishnan K.R., Husain M.M., McDonald W.M., Doraiswamy P.S., Figiel G.S., Boyko O.B., et al. In vivo stereological assessment of caudate volume in man Effect of normal aging . Life Sci. 47:1990;1325-1329.
57. Kuhn W., Heye N., Muller T., Kraus P., Klotz P., Friedrich G., et al. The motor performance test series in Parkinson's disease is influenced by depression. J Neural Transm. 103:1996;349-354.
58. Kuhn W., Hummel T., Woitalla D., Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 56:2001;281-282. [comment].
59. Kuhn W., Roebroek R., Blom H., van Oppenraaij D., Przuntek H., Kretschmer A., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 40:1998;225-227.
60. Kuopio A.M., Marttila R.J., Helenius H., Toivonen M., Rinne U.K. The quality of life in Parkinson's disease. Mov Disord. 15:2000;216-223.
61. Kuzis G., Sabe L., Tiberti C., Leiguarda R., Starkstein S.E. Cognitive functions in major depression and Parkinson disease. Arch Neurol. 54:1997;982-986.
62. Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand. 45:1969;109-113.
63. Lauterbach E.C., Jackson J.G., Price S.T., Wilson A.N., Kirsh A.D., Dever G.E. Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions. J Neuropsychiatry Clin Neurosci. 9:1997;259-266.
64. Leentjens A.F., Marinus J., Van Hilten J.J., Lousberg R., Verhey F.R. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease A discriminant analytic approach . J Neuropsychiatry Clin Neurosci. 15:2003;74-77.
65. Leentjens A., Verhey F., Lousberg R., Spitsbergen H., Wilmink F. The validity of the Hamilton and Montgomery-Asberg depression rating scales and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 15:2000;644-649.
66. Leentjens A.F., Verhey F.R., Luijckx G.J., Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 15:2000;1221-1224.
67. Lefebvre J., Loeuille G.A., Steinling M., Linquette M. Action comparee de la L-dopa et de la bromocriptine sur la T.S.H. au cours de l'hypothyroidie primitive. Nouv Presse Med. 8:1979;3033-3036.
68. Levin B.E., Llabre M.M., Weiner W.J. Parkinson's disease and depression Psychometric properties of the Beck Depression Inventory . J Neurol Neurosurg Psychiatry. 51:1988;1401-1404.
69. Lisanby S.H., McDonald W.M., Massey E.W., Doraiswamy P.M., Rozear M., Boyko O.B., et al. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. J Neural Transm Suppl. 40:1993;13-21.
70. Liu C.Y., Wang S.J., Fuh J.L., Lin C.H., Yang Y.Y., Liu H.C. The correlation of depression with functional activity in Parkinson's disease. J Neurol. 244:1997;493-498.
71. Lyness J.M., Bruce M.L., Koenig H.G., Parmelee P.A., Schulz R., Lawton M.P., et al. Depression and medical illness in late life Report of a symposium . J Am Geriatr Soc. 44:1996;198-203.
72. Lyness J.M., King D.A., Cox C., Yoediono Z., Caine E.D. The importance of subsyndromal depression in older primary care patients Prevalence and associated functional disability . J Am Geriatr Soc. 47:1999;647-652. [comment].
73. Maricle R.A., Nutt J.G., Carter J.H. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion Preliminary findings . Mov Disord. 10:1995;329-332.
74. Mayberg H.S., Starkstein S.E., Sadzot B., Preziosi T., Andrezejewski P.L., Dannals R.F., et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol. 28:1990;57-64.
75. Mayeux R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol. 53:1990;163-166.
76. Mayeux R., Stern Y., Cote L., Williams J.B. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 34:1984;642-646.
77. Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. 31:1981;645-650.
78. McDonald W.M., Krishnan K.R. Magnetic resonance in patients with affective illness. Eur Arch Psychiatry Clin Neurosci. 241:1992;283-290.
79. Meltzer H.Y., Young M., Metz J., Fang V.S., Schyve P.M., Arora R.C. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 45:1979;165-175.
80. Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry. 159:2002;746-754.
81. Menza M.A., Mark M.H. Parkinson's disease and depression The relationship to disability and personality . J Neuropsychiatry Clin Neurosci. 6:1994;165-169.
82. Menza M.A., Palermo B., DiPaola R., Sage J.I., Ricketts M.H. Depression and anxiety in Parkinson's disease Possible effect of genetic variation in the serotonin transporter . J Geriatr Psychiatry Neurol. 12:1999;49-52.
83. Menza M.A., Sage J., Marshall E., Cody R., Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord. 5:1990;148-151. [comment].
84. Middleton F.A., Strick P.L. Basal ganglia output and cognition Evidence from anatomical, behavioral, and clinical studies . Brain Cogn. 42:2000;183-200.
85. Mischoulon D., Fava M. Role of S-adenosyl-L-methionine in the treatment of depression A review of the evidence . Am J Clin Nutr. 76:2002;1158S-1161S.
86. Moellentine C., Rummans T., Ahlskog J.E., Harmsen W.S., Suman V.J., O'Connor M.K., et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 10:1998;187-193.
87. Montastruc J.L., Fabre N., Blin O., Senard J.M., Rascol O., Rascol A. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord. 10:1995;355-357.
88. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
89. Mossner R., Henneberg A., Schmitt A., Syagailo Y.V., Grassle M., Hennig T., et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry. 6:2001;350-352.
90. Muller T. Non-dopaminergic drug treatment of Parkinson's disease. Expert Opin Pharmacother. 2:2001;557-572.
91. Muller T., Werne B., Fowler B., Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 354:1999;126-127.
92. Murai T., Muller U., Werheid K., Sorger D., Reuter M., Becker T., et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 13:2001;222-228.
93. Nissenbaum H., Quinn N.P., Brown R.G., Toone B., Gotham A.M., Marsden C.D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 17:1987;899-904.
94. Okun M.S., McDonald W.M., DeLong M.R. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency A common unrecognized comorbidity . Arch Neurol. 59:2002;807-811.
95. Okun M.S., Walter B.L., McDonald W.M., Tenover J.L., Green J., Juncos J.L., et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol. 59:2002;1750-1753.
96. Olin J.T., Schneider L.S., Katz I.R., Meyers B.S., Alexopoulus G.S., Breitner J.C., et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 10:2002;125-128.
97. Otake K., Oiso Y., Mitsuma T., Hirooka Y., Adachi K. Hypothalamic dysfunction in Parkinson's disease patients. Acta Med Hung. 50:1994;3-13.
98. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 50:1991;743-755.
99. Phillips P. Keeping depression at bay helps patients with Parkinson disease. JAMA. 282:1999;1118-1119.
100. Racette B.A., Hartlein J.M., Hershey T., Mink J.W., Perlmutter J.S., Black K.J. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 14:2002;438-442.
101. Rampello L., Chiechio S., Raffaele R., Vecchio I., Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol. 25:2002;21-24.
102. Ranoux D. Depression et maladie de Parkinson. Encephale. 26:(Spec No 3):2000;22-26.
103. Reutens S., Sachdev P. Homocysteine in neuropsychiatric disorders of the elderly. Int J Geriatr Psychiatry. 17:2002;859-864.
104. Richard I.H., Justus A.W., Kurlan R. Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 13:2001;35-41.
105. Richard I.H., Kurlan R., Tanner C., Factor S., Hubble J., Suchowersky B., et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 48:1997;1070-1077.
106. Richard I.H., Maughn A., Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord. 14:1999;155-157.
107. Richard I.H., Schiffer R.B., Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 8:1996;383-392.
108. Rodriguez-Oroz M.C., Rodriguez M., Guridi J., Mewes K., Chockkman V., Vitek J., et al. The subthalamic nucleus in Parkinson's disease Somatotopic organization and physiological characteristics . Brain. 124:2001;1777-1790.
109. Rollman B.L., Reynolds C.F. 3rd. Minor and subsyndromal depression Functional disability worth treating . J Am Geriatr Soc. 47:1999;757-758. [comment].
110. Sano M., Stern Y., Williams J., Cote L., Rosenstein R., Mayeux R. Coexisting dementia and depression in Parkinson's disease. Arch Neurol. 46:1989;1284-1286.
111. Seidman S.N., Rabkin J.G. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 48:1998;157-161.
112. Simons J.A. Fluoxetine in Parkinson's disease. Mov Disord. 11:1996;581-582.
113. Slaughter J.R., Slaughter K.A., Nichols D., Holmes S.E., Martens M.P. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 13:2001;187-196.
114. Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for Axis I DSM-IV Disorders. 1994;Biometrics Research Department, New York State Psychiatric Institute, New York.
115. Starkstein S.E., Bolduc P.L., Mayberg H.S., Preziosi T.J., Robinson R.G. Cognitive impairments and depression in Parkinson's disease A follow up study . J Neurol Neurosurg Psychiatry. 53:1990;597-602.
116. Starkstein S.E., Mayberg H.S., Leiguarda R., Preziosi T.J., Robinson R.G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 55:1992;377-382.
117. Starkstein S.E., Petracca G., Chemerinski E., Teson A., Sabe L., Merello M., et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord. 13:1998;29-33.
118. Starkstein S.E., Preziosi T.J., Bolduc P.L., Robinson R.G. Depression in Parkinson's disease. J Nerv Ment Dis. 178:1990;27-31.
119. Starkstein S.E., Robinson R.G. Dementia of depression in Parkinson's disease and stroke. J Nerv Ment Dis. 179:1991;593-601.
120. Stern Y., Marder K., Tang M.X., Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology. 43:1993;1690-1692. [comment].
121. Stern Y., Richards M., Sano M., Mayeux R. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol. 50:1993;1040-1045.
122. Steur E.N. Increase of Parkinson disability after fluoxetine medication. Neurology. 43:1993;211-213.
123. Strong R. Imipramine in treatment of parkinsonism A double blind placebo study . Br Med J. 2:1965;33-34.
124. Tandberg E., Larsen J.P., Aarsland D., Cummings J.L. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol. 53:1996;175-179.
125. Tandberg E., Larsen J.P., Aarsland D., Laake K., Cummings J.L. Risk factors for depression in Parkinson disease. Arch Neurol. 54:1997;625-630.
126. Tandeter H.B., Shvartzman P. Parkinson's disease camouflaging early signs of hypothyroidism. Postgrad Med. 94:1993;187-190. [comment].
127. Tate J.L. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry. 146:1989;399-400. [comment].
128. Tenover J.L. Testosterone and the aging male. J Androl. 18:1997;103-106.
129. Tesei S., Antonini A., Canesi M., Zecchinelli A., Mariani C.B., Pezzoli G. Tolerability of paroxetine in Parkinson's disease A prospective study . Mov Disord. 15:2000;986-989.
130. Troster A.I., Stalp L.D., Paolo A.M., Fields J.A., Koller W.C. Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol. 52:1995;1164-1169.
131. Wengel S.P., Burke W.J., Pfeiffer R.F., Roccaforte W.H., Paige S.R. Maintenance electroconvulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry. 6:1998;263-269.
132. Williams J.W. Jr, Barrett J., Oxman T., Frank E., Katon W., Sullivan M., et al. Treatment of dysthymia and minor depression in primary care A randomized controlled trial in older adults . JAMA. 284:2000;1519-1526. [comment].
133. Yoshida K., Higuchi H., Kamata M., Yoshimoto M., Shimizu T., Hishikawa Y. Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Prog Neuropsychopharmacol Biol Psychiatry. 22:1998;435-444.